RT Journal Article
SR Electronic
T1 The Different T-cell Receptor Repertoires in Breast Cancer Tumors, Draining Lymph Nodes, and Adjacent Tissues
JF Cancer Immunology Research
JO Cancer Immunol Res
FD American Association for Cancer Research
SP 148
OP 156
DO 10.1158/2326-6066.CIR-16-0107
VO 5
IS 2
A1 Wang, Ting
A1 Wang, Changxi
A1 Wu, Jinghua
A1 He, Chenyang
A1 Zhang, Wei
A1 Liu, Jiayun
A1 Zhang, Ruifang
A1 Lv, Yonggang
A1 Li, Yongping
A1 Zeng, Xiaojing
A1 Cao, Hongzhi
A1 Zhang, Xiuqing
A1 Xu, Xun
A1 Huang, Chen
A1 Wang, Ling
A1 Liu, Xiao
YR 2017
UL http://cancerimmunolres.aacrjournals.org/content/5/2/148.abstract
AB T lymphocytes infiltrate the microenvironment of breast cancer tumors and play a pivotal role in tumor immune surveillance. Relationships between the T-cell receptors (TCR) borne by T cells within tumors, in the surrounding tissues, and in draining lymph nodes are largely unexplored in human breast cancer. Consequently, information about the relative extent of possible T-cell exchange between these tissues is also lacking. Here, we have analyzed the TCR repertoire of T cells using multiplex PCR and high-throughput sequencing of the TCRβ chain in the tissues of tumor, adjacent nontumor, and axillary lymph nodes of breast cancer patients. T-cell repertoire diversity in tumors was lower than in lymph nodes, but higher than in nontumor tissue, with a preferential use of variable and joining genes. These data are consistent with the hypothesis that most of the T cells in tumors derive from the lymph node, followed by their expansion in tumor tissue. Positive nodes appeared to enhance T-cell infiltration into tumors and T-cell clonal expansion in lymph nodes. Additionally, the similarity in TCR repertoire between tumor and nontumor tissue was significantly higher in luminal-like, rather than basal-like, breast cancer. Our study elucidated the high heterogeneity of the TCR repertoire and provides potential for future improvements in immune-related diagnosis, therapy, and prognosis for breast cancer patients. Cancer Immunol Res; 5(2); 148–56. ©2016 AACR.